Hudbay Minerals Inc. Ordinary Shares (Canada) vs Neurocrine Biosciences Inc — how do they compare? Hudbay Minerals Inc. Ordinary Shares (Canada) trades at $26.27 (market cap $11.24B), while Neurocrine Biosciences Inc trades at $142.6 (market cap $14.36B). The key difference: Neurocrine Biosciences Inc is the larger of the two by market cap, and Hudbay Minerals Inc. Ordinary Shares (Canada) pays a 0.11% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hudbay Minerals Inc. Ordinary Shares (Canada) for 0 Days and Neurocrine Biosciences Inc for 23 Days on average.
| HBM | NBIX | |
|---|---|---|
Market Cap | $11.24B | $14.36B |
Volume | 4,316,374 | 1,237,180 |
Sector | Basic Materials | Health |
52-Week High | $31.87 | $185.50 |
52-Week Low | $14.58 | $123.10 |
Typical Hold Time | 0 Days | 23 Days |
Enterprise Value | $11.30B | $14.37B |
Dividend Yield | 0.11% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Neurocrine Biosciences (NBIX) trades at $141.69, down 1.24% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 20.91% net income margin and consistent earnings beats, including a significant Q2 2026 beat. Recent news highlights pipeline advancements and executive appointments, while analyst sentiment remains overwhelmingly positive.
The outlook for NBIX is supported by robust fundamentals and strong analyst buy ratings, but near-term price action is challenged by technical bearishness. Key opportunities include product diversification and pipeline growth, while risks involve execution of expansion plans and potential pricing pressures on key products like INGREZZA.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Hudbay Minerals is a mining company producing copper, gold, zinc, and other metals. Its operations are located in the Americas.
Read more on HBM →Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →